The University of Lille’s Foundation awards the Hemerion Therapeutics founders for their scientific and entrepreuneurship involvement establishing a healthtech company.
The Hemerion’s founders enter the Eurasanté entrepreneurship program, an incubator dedicated to health start-up companies
Hemerion joins the Voisin Consulting Neighborhood program, a life science innovation center that offers tailored mentoring, coaching and global access to health tech entrepreneurs.
Hemerion is awarded during I-Lab innovation competition and granted to upgrade its lead product and better meet neurosurgeons needs.
Ground breaking preliminary results from the clinical study are published in the Journal of Neuro-Oncology. The Hemerion’s technology covered the 2018’s May issue. Read more
The clinical world premiere is highlighted in Nature’s 2018 September issue. An article detailing the clinical trial INDYGO and the technology being developed to treat glioblastomas is published in a special issue of journal (https://www.nature.com/articles/d41586-018-06713-6)
The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.
The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.
M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.